GWS
BIIB icon

Greykasell Wealth Strategies’s Biogen BIIB Stock Holding History

Greykasell Wealth Strategies’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.6K Hold
385
– – 0.03% 220
2025
Q4 		$67.8K Hold
385
– – 0.03% 215
2025
Q3 		$53.9K Sell
385
-120
-24% -$16.2K 0.02% 201
2025
Q2 		$63.4K Buy
505
+307
+155% +$38.3K 0.03% 183
2025
Q1 		$27.1K Buy
+198
New +$28.3K 0.01% 205

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Greykasell Wealth Strategies's BIIB Position: Q1 2026 in Review

Greykasell Wealth Strategies held its Biogen (BIIB) position steady in Q1 2026 at 385 shares worth $70.6K. The position accounts for 0.03% of the portfolio, ranked #220.

Greykasell Wealth Strategies first reported a position in BIIB in Q1 2025 and has held it in 5 quarters since. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Greykasell Wealth Strategies held 385 shares of Biogen worth $70.6K as of Q1 2026.
  • Greykasell Wealth Strategies left its Biogen share count unchanged in Q1 2026.
  • Biogen made up 0.03% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #220 holding.
  • Greykasell Wealth Strategies first reported a position in Biogen in Q1 2025 and has held it in 5 quarters since.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.